GVRP and Yurogen Biosystems Form Strategic Partnership to Advance Antibody Discovery in India
核心洞察
GV Research Platform (搜索) (GVRP (搜索)) has announced a strategic distribution partnership with Yurogen Biosystems (搜索) to expand access to advanced antibody discovery capabilities for Indian biotechnology and pharmaceutical companies.
The collaboration will provide Indian researchers with access to Yurogen's proprietary SMab™ (搜索) single B-cell technology, enabling rapid generation of high-affinity monoclonal antibodies (搜索) for early-stage drug discovery.
GVRP (搜索) will serve as the commercial interface in India while Yurogen continues scientific execution, responding to growing demand for globally benchmarked antibody discovery services in India's life sciences ecosystem.
GV Research Platform (搜索) (GVRP (搜索)) has announced a strategic distribution partnership with Yurogen Biosystems (搜索), a global life sciences company specializing in custom biologics development, to expand access to advanced antibody discovery capabilities for Indian biotechnology and pharmaceutical companies as well as academic research institutions.
Under the partnership agreement, GVRP (搜索) will serve as the commercial interface for Yurogen Biosystems (搜索) in India, enabling streamlined market access, client engagement, and program coordination, while Yurogen Biosystems will continue to handle all scientific execution and service delivery.
Addressing Growing Market Demand
The collaboration responds to the growing demand within India's life sciences ecosystem for globally benchmarked antibody discovery services, particularly in areas requiring deep biological insight at early stages of research. By combining Yurogen's scientific expertise with GVRP (搜索)'s understanding of the Indian research ecosystem, the partnership aims to enable smoother and more efficient engagement for domestic innovators.
"This partnership with Yurogen Biosystems (搜索) reflects our focus on expanding meaningful access to advanced monoclonal antibody discovery platforms such as SMab™ (搜索)," said Kalyan Korisapati, Co-Founder & CEO of GV Research Platform (搜索). "By enabling faster and more precise early discovery, we aim to support Indian innovators in advancing targeted therapies efficiently. As the local commercial interface, GVRP (搜索) will simplify engagement and facilitate access to globally benchmarked discovery capabilities."
Advanced Technology Platform
The partnership provides access to Yurogen Biosystems (搜索)' proprietary SMab™ (搜索) single B-cell technology, which enables rapid generation of high-affinity monoclonal antibodies (搜索) to support early discovery and translational research programs. The platform offers end-to-end antibody development capabilities with customized antibody engineering and production supported by comprehensive antibody-based solutions for research, diagnostics, and antibody-related drug development applications.
The collaboration includes broad monoclonal antibody capabilities for the development of rabbit, camelid (llama), and fully human monoclonal antibodies (搜索) tailored for diverse biological targets and therapeutic strategies. The platform features optimized workflows designed to reduce development timelines while maintaining high performance, reproducibility, and scientific rigor required for early-stage biologics research.
Flexible Engagement Models
The partnership offers flexible and clearly structured programs with engagement models designed to ensure clarity on ownership and freedom to operate. Antibody clones and related research outputs are delivered without IP encumbrances from the platform, providing researchers with accelerated discovery timelines through optimized workflows.
Dr. Yang Lou, CEO of Yurogen Biosystems (搜索), commented on the partnership: "India is emerging as an important centre for early-stage biomedical research. Partnering with GVRP (搜索) allows us to engage more closely with the Indian biopharma community through a trusted local presence, while continuing to deliver our services with the same scientific rigour and quality standards."
Supporting India's Drug Discovery Ecosystem
Through this partnership, GVRP (搜索) and Yurogen Biosystems (搜索) aim to strengthen global scientific collaboration and support the continued growth of India's drug discovery ecosystem by improving access to specialized early discovery capabilities. The initiative is positioned to fortify India's drug discovery infrastructure and bolster the nation's biopharma landscape by widening the scope for Indian biotech and pharmaceutical sectors in enhancing early-stage drug discovery capabilities.